Position of the Transparency Council – Ozurdex (dexamethasone)

At its meeting on 08 August 2022 the Transparency Council adopted Position No. 71/2022 on the evaluation of the drug Ozurdex (dexamethasone) under the drug programme “Treatment of uveitis – intermediate part, posterior segment or entire uvea (ICD-10 H20.0, H30.0)”.

Publication in Public Information Bulletin (BIP)